Salsolinol, a catechol neurotoxin, induces modification of ferritin: Protection by histidine dipeptide

Environmental Toxicology and Pharmacology

Volumn 29, Issue 3, 2010, Pages 246-251

  Kang, Jung Hoon ^a  

^a Chongju University   (South Korea)

Author keywords

Carnosine; Ferritin; Free radical; Salsolinol

Indexed keywords

ACETYLCARNOSINE; CARBONYL DERIVATIVE; CARNOSINE; DIPEPTIDE; FERRITIN; FREE RADICAL; SALSOLINOL; SCAVENGER; TYROSINE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; INCUBATION TIME; INHIBITION KINETICS; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN MODIFICATION; TIME;

MAMMALIA;

EID: 77951977460     PISSN: 13826689     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.etap.2010.01.007     Document Type: Article

References (54)

1. Alhamdani M.S., Al-Kassir A.H., Abbas F.K., Jaleel N.A., Al-Taee M.F. Antiglycation and antioxidant effect of carnosine against glucose degradation products in peritoneal mesothelial cells. Nephron. Clin. Pract. 2007, 107:c26-34.
2. Auroma O.I., Laughton M.J., Halliwell B. Carnosine, homocarnosine and anserine: could they act as antioxidants in vivo?. Biochem. J. 1989, 264:863-869.
3. Babizhayev M.A., Seguin M.-C., Gueyne J., Estigneeva R.P., Ageyeva E.A., Zheltukhina G.A. l-Carnosine (beta-alanyl-l-histidine) and carcinine (beta-alanylhistamine) act as natural antioxidants with hydroxyl-radical-scavenging and lipid-peroxidase activities. Biochem. J. 1994, 304:509-516.
4. Babusikova E., Hatok J., Dobrota D., Kaplan P. Age-related oxidative modifications of proteins and lipids in rat brain. Neurochem. Res. 2007, 32:1351-1356.
5. Bartzokis G., Tishler T.A., Shin I.S., Lu P.H., Cummings J.L. Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases. Ann. NY Acad. Sci. 2004, 1012:224-236.
6. Berlett, B.S., Stadtman, E.R., 1997. Protein oxidation in aging, disease, and oxidative stress.
7. Chasteen N.D. Ferritin. Uptake, storage, and release of iron. Metal Ions Biol. Syst. 1998, 35:479-514.
8. Danielson S.R., Andersen J.K. Oxidative and nitrative protein modifications in Parkinson's disease. Free Radic. Biol. Med. 2008, 44:1787-1794.
9. Decker E.A., Livisay S.A., Zhou S. Re-evaluation of the antioxidant activity of purified carnosine. Biochemistry (Moscow) 2000, 65:766-771.
10. DeCuypere M., Lu Y., Miller D.D., LeDoux M.S. Regional distribution of tetrahydroisoquinoline derivatives in rodent, human, and Parkinson's disease brain. J. Neurochem. 2008, 107:1398-1413.
11. Epp L.M., Marvec B. Chronic polysystemic candidiasis as a possible contributor to onset of idiopathic Parkinson's disease. Bratisl. Lek. Listy. 2006, 107:227-230.
12. Friguet B., Szweda L.I., Stadtman E.R. Susceptibility of glucose-6-phosphate dehydrogenase modified by 4-hydroxy-2-nonenal and metal-catalyzed oxidation to proteolysis by the multicatalytic protease. Arch. Biochem. Biophys. 1994, 311:168-173.
13. Friguet B., Bulteau A.L., Petropoulos I. Mitochondrial protein quality control: implications in ageing. Biotechnol. J. 2008, 3:757-764.
14. Galaris D., Pantopoulos K. Oxidative stress and iron homeostasis: mechanistic and health aspects. Crit. Rev. Clin. Lab. Sci. 2008, 45:1-23.
15. Gotz M.E., Kunig G., Riderer P., Youdim M.B. Oxidative stress: free radical production in neural degeneration. Pharmacol. Ther. 1994, 63:37-122.
16. Granier T., Langlois, d'Estaintot B., Gallois B., Chevalier J.M., Precigoux G., Santambrogio P., Arosio P. Structural description of the active sites of mouse L-chain ferritin at 1.2A resolution. J. Biol. Inorg. Chem. 2003, 8:105-111.
17. Halliwell, B., Gutteridge, J.M.C., 2007. Oxidative stress and antioxidant protection: some special cases. Free Radic. Biol. Med., New York, Oxford, pp. 333-336.
18. Harrison P.M., Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim. Biophys. Acta 1996, 1275:161-203.
19. Hartman P.E., Hartman Z., Ault K.T. Scavenging of singlet molecular oxygen by imidazole compounds: high and sustained activities of carboxy terminal histidine dipeptides and exceptional activity of imidazole-4-acetic acid. Photochem. Photobiol. 1990, 51:59-66.
20. Hipkiss A.R. Could carnosine or related structures suppress Alzheimer's disease?. J. Alzheimer's Dis. 2007, 11:229-240.
21. Hipkiss A.R., Brownson C., Carrier M.J. Carnosine, the anti-ageing, anti-oxidant dipeptide, may react with protein carbonyl groups. Mech. Ageing Dev. 2001, 122:1431-1445.
22. Hugli T.E., Moore S. Determination of the tryptophan content of proteins by ion exchange chromatography of alkaline hydrolysates. J. Biol. Chem. 1972, 247:2828-2834.
23. Kang J.H., Kim K.S., Choi S.Y., Kwon H.Y., Won M.H., Kang T.C. Carnosine and related dipeptides protect human ceruloplasmin against peroxyl radical-mediated modification. Mol. Cells 2002, 13:498-502.
24. Kim H.J., Yoon H.R., Washington S., Chang I.I., Oh Y.J., Surh Y.J. DNA strand scission and PC12 cell death induced by salsolinol and copper. Neurosci. Lett. 1997, 238:95-98.
25. Kohen R., Yamamoto Y., Cundy K.C., Ames B.N. Antioxidant activity of carnosine, homocarnosine, and anserine present in muscle and brain. Proc. Natl. Acad. Sci. U.S.A. 1988, 85:3175-3179.
26. Koziorowski D., Friedman A., Arosio P., Santambrogio P., Dziewalska D. ELISA reveals a difference in the structure of substantia nigra ferritin in Parkinson's disease and incidental Lewy body compared to control. Parkinsonism Relat. Disord. 2007, 13:214-218.
27. 4. Nature 1970, 227:680-685.
28. Levine R.L., Williams J.A., Stadtman E.R., Shacter E. Carbonyl assays for determination of oxidatively modified proteins. Methods Enzymol. 1994, 233:346-357.
29. Lopes K.O., Sparks D.L., Streit W.J. Microglial dystrophy in the aged and Alzheimer's disease brain is associated with ferritin immunoreactivity. Glia 2008, 56:1048-1060.
30. Mates J.M., Segura J.A., Alonso F.J., Marguez J. Intracellular redox status and oxidative stress: implications for cell proliferation, apoptosis, and carcinogenesis. Arch. Toxicol. 2008, 82:273-299.
31. Murray J., Oquendo C.E., Willis J.H., Marusich M.F., Capaldi R.A. Monitoring oxidative and nitrative modification of cellular proteins; a paradigm for identifying key disease related markers of oxidative stress. Adv. Drug Deliv. Rev. 2008, 60:1497-1503.
32. Nagasawa T., Yone Kura T., Nishizawa N., Kitts D.D. In vitro and in vivo inhibition of muscle lipid and protein oxidation by carnosine. Mol. Cell Biochem. 2001, 225:29-34.
33. O'Dowd J.J., Robins D.J., Miller D.J. Detection, characterisation, and quantification of carnosine and other histidyl derivatives in cardiac and skeletal muscle. Biochem. Biophys. Acta 1988, 967:241-249.
34. Pennathur S., Jackson-Lewis V., Przedborski S., Heinecke J.W. Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine, and o,o′-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease. J. Biol. Chem. 1999, 274:34621-34628.
35. Perluigi M., Joshi G., sultana R., Calabrese V., De Marco C., Coccia R.D., Butterfield A. In vivo protection by the xanthate tricyclodecan-9-yl-xanthogenate against amyloid beta-peptide (1-42)-induced oxidative stress. Neuroscience 2006, 138:1161-1170.
36. Rajanikant G.K., Zemke D., Senut M.C., Frenkel M.B., Chen A.F., Gupta R., Majid A. Carnosine is neuroprotective against permanent focal cerebral ischemia in mice. Stroke 2007, 38:3023-3031.
37. Reddy V.P., Garrett M.R., Perry G., Smith M.A. Carnosine: a versatile antioxidant and antiglycating agent. Sci. Aging Knowledge Environ. 2005, 4:pe12.
38. Reznick A.Z., Packer L. Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Methods Enzymol. 1994, 233:357-363.
39. Rucker P., Torti F.M., Torti S.V. Role of H and L subunits in mouse ferritin. J. Biol. Chem. 1996, 271:33352-33357.
40. Ruf R.A., Lutz E.A., Zigoneanu I.G., Pielak G.J. Alpha-synuclein conformation affects its tyrosine-dependent oxidative aggregation. Biochemistry 2008, 47:13604-13609.
41. Sandler M.M., Carter S.B., Hunter K.R., Stern G.M. Tetrahydroisoquinoline alkaloids, in vivo metabolites of l-DOPA in man. Nature 1973, 241:439-443.
42. Santambrogio P., Levi S., Cozzi A., Rovida E., Albertini A., Arosio P. Production and characterization of recombinant heteropolymers of human ferritin H and L chains. J. Biol. Chem. 1993, 268:12744-12748.
43. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.-H., Provenzano M.D., Fujimoto E.K., Goeke N.M., Olson B.J., Klenk D.C. Measurement of protein using bicinchoninic acid. Anal. Biochem. 1985, 150:76-85.
44. Smith D.G., Cappai R., Barnham K.J. The redox chemistry of the Alzheimer's disease amyloid beta peptide. Biochim. Biophys. Acta 2007, 1768:1976-1990.
45. Soto-Otero R., Sanmartin-Suarez C., Sanchez-Iglesias S., Hermida-Ameijeiras A., Sanchez-Sellero I., Mendez-Alvarez E. Study on the ability of 1,2,3,4-tetrahydropapaveroline to cause oxidative stress: mechanisms and potential implications in relation to Parkinson's disease. J. Biochem. Mol. Toxicol. 2006, 20:209-220.
46. Stadtman E.R. Oxidation of free amino acids and amino acid residues in proteins by radiolysis and by metal-catalyzed reactions. Annu. Rev. Biochem. 1993, 62:797-821.
47. Surh Y.J., Jung Y.J., Jung J.H., Lee J.S., Yoon H.R. Iron enhancement of oxidative DNA damage and neuronal cell death induced by salsolinol. J. Toxicol. Environ. Health Part A 2002, 65:473-488.
48. Theil E.C. The ferritin family of iron storage proteins. Adv. Enzymol. Relat. Areas Mol. Biol. 1990, 63:421-449.
49. Thomas M., Jankovic J. Neurodegenerative disease and iron storage in the brain. Curr. Opin. Neurol. 2004, 17:437-442.
50. Uchida K., Stadtman E.R. Covalent attachment of 4-hydroxynonenal to glyceraldehyde-3-phosphate dehydrogenase. A possible involvement of intra- and intermolecular cross-linking reaction. J. Biol. Chem. 1993, 268:6388-6393.
51. Velez S., Nair N.G., Reddy V.P. Transition metal ion binding studies of carnosine and histidine: biologically relevant antioxidants. Colloids Surf. B: Biointerfaces 2008, 66:291-294.
52. Wallis L.I., Paley M.N., Graham J.M., Grunewald R.A., Wignall E.L., Joy H.M., Griffiths P.D. MRI assessment of basal ganglia iron deposition in Parkinson's disease. J. Magn. Reason Imag. 2008, 28:1061-1067.
53. Wanpen S., Koonccumchoo P., Shrali S., Govitrapong P., Ebadi M. Salsolinol a dopamine-derived tetrahydroquindine induces cell death by causing oxidative stress in dopaminergic SH-SY5Y cells, and the said effect is attenuated by metallothionein. Brain Res. 2004, 1005:67-76.
54. Zecca L., Youdim M.B., Riederer P., Connor J.R., Crichton R.R. Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 2004, 5:863-873.